How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 63.6 | 63.6 | 63.6 | 64.4 | 64.4 | 64.4 | +0.8 |
| Healthcare | 24.2 | 24.2 | 24.2 | 24.2 | 24.2 | 24.2 | -0.0 |
| Chemicals | 4.2 | 4.2 | 4.2 | 4.3 | 4.3 | 4.3 | +0.1 |
| FMCG | 2.8 | 2.8 | 2.8 | 2.7 | 2.7 | 2.7 | -0.2 |
| Unclassified | 2.5 | 2.5 | 2.5 | 2.2 | 2.2 | 2.2 | -0.3 |
| Defence | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | -0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| DIVISLAB | Pharma | 9.67% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| SUNPHARMA | Pharma | 8.87% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| PPLPHARMA | Pharma | 6.60% | 10 | 1 | 5 | 9 | 5 | Leader | +28.4% |
| APOLLOHOSP | Healthcare | 6.50% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| AUROPHARMA | Pharma | 6.13% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| RUBICON | Pharma | 6.01% | 7 | 8 | 5 | 4 | 1 | — | +43.6% |
| TORNTPHARM | Pharma | 5.48% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| NEULANDLAB | Healthcare | 4.42% | 8 | 10 | 7 | 4 | 1 | — | +30.4% |
| EMCURE | Pharma | 4.37% | 10 | 10 | 9 | 10 | 4 | Leader | +7.6% |
| MAXHEALTH | Healthcare | 3.80% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| FORTIS | Healthcare | 3.01% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| ZYDUSWELL | FMCG | 2.66% | 5 | 2 | 4 | 9 | 3 | — | +1.7% |
| LAURUSLABS | Pharma | 2.41% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| IPCALAB | Pharma | 2.34% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| VIJAYA | Pharma | 2.20% | 7 | 10 | 5 | 4 | 1 | — | +10.1% |
| SENORES | Pharma | 2.11% | 9 | 10 | 8 | 4 | 2 | Leader | +44.3% |
| SHAILY | Chemicals | 2.02% | 10 | 10 | 3 | 4 | 1 | Leader | +4.3% |
| NAVINFLUOR | Chemicals | 2.01% | 9 | 10 | 4 | 8 | 1 | Leader | +20.9% |
| LALPATHLAB | Healthcare | 1.78% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| GLAXO | Healthcare | 1.68% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| GLENMARK | Pharma | 1.64% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| DRREDDY | Pharma | 1.37% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| ZYDUSLIFE | Pharma | 1.33% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| BIOCON | Pharma | 1.29% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| KIMS | Healthcare | 1.07% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| MEDIASSIST | Healthcare | 0.96% | 4 | 7 | 9 | 8 | 7 | — | -8.2% |
| ONESOURCE | Healthcare | 0.95% | 3 | 1 | 6 | 7 | 8 | — | -15.1% |
| JUBLPHARMA | Pharma | 0.87% | 3 | 1 | 3 | 3 | 7 | — | -5.2% |
| TURTLEMINT | — | 0.83% | — | 2 | 1 | 4 | 4 | — | — |
| SUMICHEM | Chemicals | 0.27% | 6 | 7 | 1 | 5 | 4 | — | +1.6% |
Performance · 1.7y
Over the last 1.7 years ₹100 in the fund grew to ₹119 (+19%), vs ₹104 for Nifty 500 (+4%) and ₹101 for Nifty 50 (+1%). Its relative-strength line ended at 118 vs Nifty 50 and 115 vs Nifty 500 — above 100, sustained outperformance.